{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:32Z","timestamp":1780987952614,"version":"3.54.1"},"reference-count":99,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The T-cell lymphomas are a rare group of Non-Hodgkin\u2019s lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.<\/jats:p>","DOI":"10.3390\/jpm11060481","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T11:07:02Z","timestamp":1622113622000},"page":"481","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted Approaches to T-Cell Lymphoma"],"prefix":"10.3390","volume":"11","author":[{"given":"Sean","family":"Harrop","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8848-9423","authenticated-orcid":false,"given":"Chathuri","family":"Abeyakoon","sequence":"additional","affiliation":[{"name":"Monash Health, Melbourne, VIC 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Van Der Weyden","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"},{"name":"Epworth Healthcare, Melbourne, VIC 3002, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Abeyakoon, C., van der Weyden, C., Harrop, S., Khot, A., Dickinson, M., Yannakou, C.K., and Prince, H.M. (2020). Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12113125"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fonc.2019.00443","article-title":"Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas","volume":"9","author":"Crisci","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and S\u00e9zary Syndrome with Variable CD30 Expression Level: A Multi-Institution Collaborative Project","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab Vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-134398","article-title":"The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma","volume":"136","author":"Horwitz","year":"2020","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2017-10-811083","article-title":"ALCL: Is it now a curable disease?","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/hon.96_2630","article-title":"Final data from the phase 3 Alcanza study: Brentuximab vedotin (BV) vs physician\u2019s choice (PC) in patients (PTS) with cd30-positive (CD30+) cutaneous T-cell lymphoma (CTCL)","volume":"37","author":"Horwitz","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1200\/JCO.2019.37.15_suppl.7543","article-title":"Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas","volume":"37","author":"Jagadeesh","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00011-017-1032-8","article-title":"The immunological function of CD52 and its targeting in organ transplantation","volume":"66","author":"Zhao","year":"2017","journal-title":"Inflamm. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/cmi.2013.38","article-title":"CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells","volume":"10","author":"Samten","year":"2013","journal-title":"Cell. Mol. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2018-99-112076","article-title":"Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1\/2 Phase III Trials","volume":"132","author":"Altmann","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab\u2013CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kooy","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: The DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2020","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428190903580402","article-title":"A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas","volume":"51","author":"Weidmann","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"Guitera","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: Clinical and immunologic findings in 14 patients","volume":"92","author":"Pietro","year":"2007","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 Expression in Cutaneous T Cell Lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1\u2013transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"ref_33","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator\u2019s choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Adrienne","year":"2019","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2014-09-598995","article-title":"KIR3DL2 is a coinhibitory receptor on S\u00e9zary syndrome malignant T cells that promotes resistance to activation-induced cell death","volume":"124","author":"Thonnart","year":"2014","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1158\/0008-5472.CAN-14-1456","article-title":"IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma","volume":"74","author":"Viaud","year":"2014","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: An international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"ref_43","first-page":"2590","article-title":"Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells","volume":"56","author":"Re","year":"1996","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients with Cutaneous T-Cell Lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2019-121723","article-title":"Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma","volume":"134","author":"Maruyama","year":"2019","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2353\/ajpath.2009.080755","article-title":"EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues","volume":"174","author":"Martelli","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK\u2212 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in Anaplastic Large-Cell Lymphoma","volume":"364","author":"Messa","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_50","first-page":"djt378","article-title":"Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase\u2013Positive Lymphoma Patients","volume":"106","author":"Farina","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bossi, E., Aroldi, A., Brioschi, F.A., Steidl, C., Baretta, S., Renso, R., Verga, L., Fontana, D., Sharma, G.G., and Mologni, L. (2020). Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed\/refractory to chemotherapy. Am. J. Hematol., 95.","DOI":"10.1002\/ajh.25967"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s40425-018-0457-0","article-title":"PI3K\u03b1\/\u03b4 inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity","volume":"6","author":"Carnevalli","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","article-title":"Phosphoinositide 3-kinase delta (PI3K\u03b4) in leukocyte signaling and function","volume":"23","year":"2011","journal-title":"Cell. Signal."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The Combination of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, and Romidepsin Is Highly Active in Relapsed\/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.annonc.2020.12.009","article-title":"Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): An open-label phase I\/II trial","volume":"32","author":"Yhim","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Huen, A., Haverkos, B.M., Zain, J., Radhakrishnan, R., Lechowicz, M.J., Devata, S., Korman, N.J., Pinter-Brown, L., Oki, Y., and Barde, P.J. (2020). Phase I\/Ib Study of Tenalisib (RP6530), a Dual PI3K \u03b4\/\u03b3 Inhibitor in Patients with Relapsed\/Refractory T-Cell Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12082293"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.14984","article-title":"Mutations in the JAK\/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma","volume":"183","author":"Manso","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00403-020-02062-5","article-title":"The polymorphisms of IL-6\/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility","volume":"313","author":"Olszewska","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/leu.2009.198","article-title":"Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin\u2019s lymphoma cell lines","volume":"24","author":"Wilcox","year":"2010","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood-2019-125017","article-title":"Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood-2018-99-119944","article-title":"The Novel SYK\/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed\/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.1302059","article-title":"Development of innate CD4+ and CD8+ T cells in Itk-deficient mice is regulated by distinct pathways","volume":"193","author":"Prince","year":"2014","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nri1591","article-title":"TEC-family kinases: Regulators of T-helper-cell differentiation","volume":"5","author":"Schwartzberg","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/bloodadvances.2017011916","article-title":"Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-137782","article-title":"(Hons) C.K.; Radeski, M.D.; Kim, Y.H.; Mehta-Shah, N.; Khot, M.A.; Wilcox, R.A.; Kim, W.S.; et al. Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma","volume":"136","author":"Khodadoust","year":"2020","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Prince, H.M., Zain, J., Younes, A., Whittaker, S., O\u2019Connor, O.A., and Harrop, S. (2021). Epigenetics of T-cell Lymphoma. Peripher. T-Cell Lymphomas, 7\u201345.","DOI":"10.1002\/9781119671336.ch3"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10637-010-9596-y","article-title":"Histone deacetylase inhibitors: Potential targets responsible for their anti-cancer effect","volume":"28","author":"Dickinson","year":"2010","journal-title":"Investig. New Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2006","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final Results from a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-134440","article-title":"Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma","volume":"136","author":"Bachy","year":"2020","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/hon.8_2632","article-title":"Multi-center phase II study of oral azacitidine (CC-486) plus chop as initial treatment for peripheral T-cell lymphoma","volume":"37","author":"Ruan","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2019-126194","article-title":"A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients with Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood-2019-132278","article-title":"A Phase I\/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: Clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-genome sequencing identifies responders to Pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/jco.2015.33.15_suppl.8521","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma: Activity in T-cell lymphoma","volume":"33","author":"Lunning","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): Report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Sun, Y., Li, L., Li, X., Zhang, L., Wang, X., Fu, X., Sun, Z., Zhang, X., Li, Z., and Wu, J. (2020). Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients. Ther. Adv. Med. Oncol., 12.","DOI":"10.1177\/1758835920923829"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5694\/mja2.50783","article-title":"Chimeric antigen receptor T-cell therapy for haematological malignancies","volume":"213","author":"Selim","year":"2020","journal-title":"Med. J. Aust."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: Challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/6\/481\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:02Z","timestamp":1760162942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/6\/481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":99,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jpm11060481"],"URL":"https:\/\/doi.org\/10.3390\/jpm11060481","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]}}}